IP Library Granted Patent US 7,186,552
Granted Patent B2
US 7,186,552 · App. 10/696,900 · Granted Mar 6, 2007

Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same

Assignee: The Trustees of University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,552
App. No.
10/696,900
Granted
Mar 6, 2007
Kind
B2
Abstract

The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.

Claims (15)

1. A recombinant vector comprising a 5′ AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell, wherein said ITR has the sequence consisting of:

nt 1 to 143 of SEQ ID NO: 1.

2. The recombinant vector according to claim 1 , wherein said vector further comprises a 3′ AAV-1 ITR.

3. The recombinant vector according to claim 1 , wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17.

4. The recombinant vector according to claim 1 , wherein said vector further comprises adenovirus sequences.

5. A recombinant vector comprising a 3′ AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell, wherein said ITR has the sequence of:

nt 4576 to 4718 of SEQ ID NO: 1.

6. The recombinant vector according to claim 5 , wherein said vector further comprises a 5′ AAV-1 ITR.

7. An isolated host cell transduced with the recombinant vector according to claim 3 .

8. A composition comprising a recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID No: 13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO: 15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO: 17 and a heterologous molecule which comprises an AAV 5′ inverted terminal repeat sequence (ITR), a transgene, and an AAV 3′ ITR.

9. The composition of claim 8 wherein the AAV-1 protein vp1 is encoded by a nucleic acid having at least 98% identity to nucleotides 2223–4431 of SEQ ID NO: 1.

10. The composition of claim 8 wherein the AAV-1 protein vp2 is encoded by a nucleic acid having at least 98% identity to nucleotides 2634–4432 of SEQ ID NO: 1.

11. The composition of claim 8 wherein the AAV-1 protein vp3 is encoded by a nucleic acid having at least about 98% identity to nucleotides 2829–4432 of SEQ ID NO: 1.

12. The composition of claim 8 wherein the AAV 5′ ITR and 3′ ITR are of AAV serotype 2.

13. The composition of claim 12 wherein the recombinant virus further comprises a regulatable promoter which directs expression of the transgene.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 7, 2012
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028169/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2003
From: WILSON, JAMES M.
To: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Reel/Frame 014659/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2003
From: XIAO, WEIDONG
To: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Reel/Frame 014659/0203 →
Continuity (3)
Division 0980780200
Provisional Application 6010711400 · Nov 5, 1998
Related Publication 20040057933A1 · Mar 25, 2004